Please login to the form below

tralokinumab

This page shows the latest tralokinumab news and features for those working in and with pharma, biotech and healthcare.

AZ’s Fasenra hit by COPD trial failure

IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase III

Latest news

AZ gets EMA green light for severe asthma drug Fasenra

Prospects for IL-13 inhibitor tralokinumab look terminal after three failed late-stage trials, however, and AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase
AZ prices severe asthma drug Fasenra below competition

Prospects for IL-13 inhibitor tralokinumab look rocky after two failed late-stage trials, elevating the importance of Fasenra in those plans.
AZ severe asthma drug benralizumab backed by CHMP

Benralizumab has assumed much greater importance for the company since IL-13 inhibitor tralokinumab - another severe asthma candidate - failed two phase III trials.
Roche out-licenses lebrikizumab rights to Dermira

Disappointing results with other IL-13-targeting drugs in asthma - including Pfizer's anrukinzumab and AstraZeneca's tralokinumab - undermined confidence in the approach.
AZ trial adds to pessimism about anti-IL-13 asthma drugs

Prospects for drugs targeting interleukin-13 for asthma treatment have taken another knock after AstraZeneca's tralokinumab failed a phase III trial. ... It looks increasingly like a lost cause as AZ already reported disappointing phase IIb data with

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Leo has its eyes on the prize

Its landmark partnership with AstraZeneca and the launch of Kyntheum, the fully-human monoclonal antibody targeting psoriasis, and the phase III hope of tralokinumab for atopic dermatitis are part of an
2016: The year when deal-makers took stock?

Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business.
Deal Watch July 2016

AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis. ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13)

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Account Manager / Account Director: Competative

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Experienced Medical Writers: Competitive Salary and Benefits

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Medical Writer: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Manager- Healthcare Advertising: Negotiable

Associate Director: £75, 000-90, 000

Editorial Manager - MedComms: DOE

Business Director: Competitive Salary Offered

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Account Executive/ Senior Account Executive: competitive Salary Offfered

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Systematic Reviewer - Oxford: Negotiable

Principal Health Economist - North-West: Negotiable

Senior Editorial Assistant – Greater Manchester: DOE

Account Manager: Negotiable

Associate Medical Director: Excellent PTO, bonus and 401k package

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Account Manager / Senior Account Manager: 35, 000-40, 000

Medical (Scientific) Director: £120, 000 benefits

Account Director: Competitive Salary Offered

Subscribe to our email news alerts

PMHub

Add my company

Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Is China ready for a pharmaceutical gold rush?: Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...